Oxytocin is a nine-amino-acid peptide hormone made by neurons in the hypothalamus and released from the posterior pituitary gland. It has a small ring closed by a disulfide bond between two cysteines, with a short three-residue tail hanging off it. The molecular formula is C43H66N12O12S2 (PubChem CID 439302). It differs from the related hormone vasopressin by only two amino acids.
Unlike most compounds catalogued on this site, oxytocin is a long-established prescription drug, not a research-only chemical. The synthetic form has been sold for decades under names including Pitocin and Syntocinon.
What it does in the body
Two classic roles, both mechanical. In the uterus, oxytocin binds G-protein-coupled receptors on smooth muscle and raises intracellular calcium, triggering contractions; it also drives local prostaglandin production, which adds to the effect. Receptor density in the myometrium climbs sharply through pregnancy and peaks around term, which is part of why the same hormone has little effect on a non-pregnant uterus and a strong one during labor (StatPearls, NCBI).
The second role is milk let-down. Suckling triggers oxytocin release, which contracts the myoepithelial cells wrapped around the milk-producing alveoli and pushes milk into the ducts.
Labor itself runs on a positive feedback loop: contractions stimulate more oxytocin release, which strengthens the contractions.
Approved medical use
The FDA-approved indications for injectable oxytocin are obstetric. The Pitocin label covers inducing or augmenting labor when there is a medical reason to deliver (for example pre-eclampsia, maternal diabetes, or premature rupture of membranes), managing uterine inertia, and controlling bleeding after delivery. It is given by a clinician intravenously or intramuscularly, with IV contractions starting within about a minute. Plasma clearance is fast. None of this is dosing guidance; it is what the approved label describes.
The social-behavior research, and why it underwhelmed
Because oxytocin is involved in bonding and social signaling in animals, it became a popular candidate for conditions involving social difficulty, especially autism. Intranasal sprays were the delivery method of choice, on the theory that some peptide reaches the brain.
The enthusiasm ran ahead of the data. The largest test to date was a 24-week randomized, placebo-controlled trial by Sikich and colleagues, published in the New England Journal of Medicine in 2021. It enrolled 290 children and adolescents aged 3 to 17 with autism spectrum disorder. The change in the primary social-withdrawal measure was essentially identical in the oxytocin and placebo groups (P = 0.61), with no separation on secondary outcomes either. Earlier small studies had hinted at benefit; the big, rigorous one did not confirm it. Reviews across the field describe the effects as small, inconsistent, and poorly replicated.
So oxytocin is an approved drug for one narrow set of uses and an unproven one for the social and psychiatric uses it is often marketed around. It is not approved for those purposes.
Quality and sourcing notes
peptideone does not sell oxytocin, test it, or give medical or dosing advice. Where it appears as a "research peptide" rather than a pharmacy product, the same caution applies as for anything in that gray market: the vial is only as good as its identity and purity. A nine-residue peptide with a defined disulfide ring can be misfolded, oxidized, or underfilled, and none of that is visible by eye. A current third-party certificate of analysis showing identity (typically mass spec) and purity (typically HPLC) for the specific lot is the minimum worth asking for. Material sold this way is labeled research-use-only and not for human consumption.
Nothing here is medical or dosing advice.